EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Tony Z Zhuang iD, Deepak Ravindranathan, Yuan Liu, Dylan J Martini, Jacqueline T Brown, Bassel Nazha iD, Greta Russler, Lauren B Yantorni, Sarah Caulfield, Bradley C Carthon, Omer Kucuk, Viraj A Master und 1 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyac236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Tony Z Zhuang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biomarkers have the potential to guide treatment selection and clinical care in metastatic renal cell carcinoma (mRCC) in an expanding treatment landscape. We report baseline neutrophil-to-eosinophil ratios (NER) in patients with mRCC treated with immune checkpoint inhibitors (CPIs) and their association with clinical outcomes.

Methods

We conducted a retrospective review of patients with mRCC treated with CPIs at Winship Cancer Institute from 2015 to 2020 in the United States of America (USA). Demographics, disease characteristics, and laboratory data, including complete blood counts (CBC) were described at the initiation of CPIs. Clinical outcomes were measured as overall survival (OS), progression-free survival (PFS), and clinical benefit (CB) associated with baseline lab values.

Results

A total of 184 patients were included with a median follow-up time of 25.4 months. Patients with baseline NER were categorized into high or low subgroups; high group was defined as NER >49.2 and low group was defined as NER <49.2 with 25% of patients in the high NER group. Univariate analyses (UVA) and multivariable analyses (MVA) identified decreased overall survival (OS) associated with elevated NER. In MVA, patients with a high baseline NER group had a hazard ratio (HR) of 1.68 (95%CI, 1.01-2.82, P = .048) for OS; however, there was no significant difference between groups for PFS. Clinical benefit was seen in 47.3% of patients with low baseline NER and 40% with high NER.

Conclusions

We conclude that elevated baseline NER may be associated with worse clinical outcomes in mRCC. Although results require further validation, NER is a feasible biomarker in patients with CPI-treated mRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansImmune Checkpoint InhibitorsNeutrophilsEosinophilsRetrospective Studies

Stichwörter der Autor:innen

biomarkercheckpoint inhibitorimmunotherapynivolumabrenal cell carcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
  • Grady Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, GA, USA.
  • Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
  • Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.

ORCID-Profile: Tony Z Zhuang, Bassel Nazha

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Institutes of Health
  • Emory University

Zitieren

APA

Zhuang, T. Z., Ravindranathan, D., Liu, Y., Martini, D. J., Brown, J. T., Nazha, B., Russler, G., Yantorni, L. B., Caulfield, S., Carthon, B. C., Kucuk, O., Master, V. A., & Bilen, M. A. (2023). Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The Oncologist. https://doi.org/10.1093/oncolo/oyac236

Vancouver

Zhuang TZ, Ravindranathan D, Liu Y, Martini DJ, Brown JT, Nazha B, et al. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The Oncologist. 2023. doi:10.1093/oncolo/oyac236

BibTeX
@article{Zhuang2023,
  author = {Zhuang, Tony Z and Ravindranathan, Deepak and Liu, Yuan and Martini, Dylan J and Brown, Jacqueline T and Nazha, Bassel and Russler, Greta and Yantorni, Lauren B and Caulfield, Sarah and Carthon, Bradley C and Kucuk, Omer and Master, Viraj A and Bilen, Mehmet Asim},
  title = {Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyac236}
}
Kostenlos starten →